Immunotherapy Atezolizumab Receives FDA Approval for Advanced BRAF V600-Mutant MELANOMA

BRAF V600 mutation -positive, unresectable or metastatic cases of melanoma are treated with cobimetinib and vemurafenib in combination with atezolizumab (Tecentriq), an immunotherapy approved on 30 July 2020 by the US Food and Drug Administration (FDA). This is the first approved combination of BRAF inhibitors and immunotherapy.
The IMspire150 clinical trial
The efficacy of atezolizumab with cobimetinib and vemurafenib was evaluated in 514 patients in the double-blind, randomized (1:1), placebo-controlled, multicenter IMspire150 clinical trial. After a 28-day cycle of cobimetinib and vemurafenib, patients received oral tablets of 60 mg cobimetinib once daily and 720 mg vemurafenib twice daily, along with an infusion of 840 mg atezolizumab every 2 weeks or placebo. In the placebo arm, komimetinib was given as a single 60 mg dose daily (21 days on, 7 days off) and vemurafenib as 960 given 2 times daily.
The primary efficacy outcome measure was progression-free survival (PFS) in the trial.
Median PFS was 15.1 months in the atezolizumab arm and placebo patients had 10 months. Adding immunotherapy to treatment reduced the risk of cancer progression by 22%.
In patients with melanoma treated with atezolizumab in combination with cobimetinib and vemurafenib, the most common (20%) side effects were rash, musculoskeletal pain, nausea, fatigue, liver damage, pyrexia (fever), nausea, edema, stomatitis (mouth sores), hypothyroidism (thyroid dysfunction) and photosensitivity (excessive sensitivity to sunlight).
After completing a 28-day cycle of cobimetinib and vemurafenib, the recommended atezolizumab dose is 840 mg every 2 weeks. Oral cobimetinib 60 mg once daily (21 days on and 7 days off) and vemurafenib 720 mg twice daily are taken concurrently.
*
Sources
fda.gov - 30 July 2020
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.